 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| 12345678910111213...2425» |
- || Clinical, Review, Journal: Rituximab for people with multiple sclerosis. (Pubmed Central) - Mar 12, 2025
There is an increased risk of serious (hospital-treated) infections with rituximab compared with other DMTs, although the absolute risk is low. High-quality (prospectively registered) NRSIs should be conducted to draw more reliable conclusions about the potential benefits and harms of rituximab in people with MS.
- || Review, Journal: Comorbidities of hypothyroidism. (Pubmed Central) - Mar 11, 2025
Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.
- || Clinical, Retrospective data, Review, Journal: Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis (Pubmed Central) - Mar 6, 2025
Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome. Systematic literature review and network meta-analysis revealed statistically significant superiority of divozilimab over cladribine and fingolimod and absence of statistically significant differences with alemtuzumab, ocrelizumab, ofatumumab and natalizumab in the annual relapse rate during 2 years of treatment.
- | Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Journal: Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review. (Pubmed Central) - Mar 3, 2025
In conjunction with studies of the United Kingdom's and European Union's pharmacovigilance databases, these results support the current package insert for alemtuzumab in which TTP is listed as a "warning and precaution". Increased awareness of this possible side effect, and prolonged monitoring, is warranted.
- | Mavenclad (cladribine) / EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Feb 18, 2025
P=N/A, N=900, Active, not recruiting, Sponsor: Johns Hopkins University
Increased awareness of this possible side effect, and prolonged monitoring, is warranted. Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
- Lemtrada (alemtuzumab) / Sanofi
SS5. Industry Supported Satellite Symposium 5 - A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden () - Feb 16, 2025 - Abstract #ACTRIMSForum2025ACTRIMS_Forum_560;
Evaluate clinical trial data for current and emerging therapies in the management of NMOSD. Implement evidence-based approaches to modify treatment in patients with NMOSD based on treatment response.
- || Observational data, Review, Journal: Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. (Pubmed Central) - Feb 15, 2025
However, well-designed, long-term RCTs in the pediatric population are needed. The results of ongoing studies may fill the existing gap in clinical evidence, possibly leading to the approval of more highly effective DMTs for patients with POMS.
- || Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review. (Pubmed Central) - Feb 13, 2025
MAbs used in MS immunotherapy have shown to induce secondary autoimmune disorders including endocrine complications, which have been reported in many case reports. It is recommended to use these agents with caution and monitor patients for symptoms of the aforementioned conditions.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, Real-world evidence: Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. (Pubmed Central) - Feb 12, 2025
P3, P4
ClinicalTrials.gov (CARE-MS I, NCT00530348; CARE-MS II, NCT00548405; CARE-MS Extension Study, NCT00930553; TOPAZ, NCT02255656). Paul-Ehrlich-Institut (TREAT-MS, NIS 281).
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Evolving Patterns of Initial RRMS Treatment in Finland (2013-2022): Insights From a Nationwide Multiple Sclerosis Register. (Pubmed Central) - Feb 12, 2025
Paul-Ehrlich-Institut (TREAT-MS, NIS 281). In Finland, the treatment of RRMS has shifted toward earlier diagnosis and earlier initiation of heDMTs, likely improving the prognosis of the patients.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, HEOR, Real-world evidence, Real-world: Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study. (Pubmed Central) - Jan 29, 2025
This real-world study showed beneficial impact of alemtuzumab on fatigue, cognition, depression, QoL, and treatment satisfaction. Improvement in patient disability, and caregiver-reported outcomes indicated enhanced patients' QoL.
- Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Equine Anti-Thymocyte Globulin and Alemtuzumab Are Associated with the Highest Survival Among Common Induction Therapies in U.S. Lung Transplant Recipients (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1898;
While rejection / respiratory failure-related deaths were lowest with alemtuzumab (HR=0.75 [0.63-0.90], p=0.002), cancer-related deaths were increased (HR=1.39 [1.08-1.78], p=0.009), versus no induction.Conclusion Using Equine ATG or alemtuzumab as induction therapy may increase survival in lung transplant recipients, largely mediated by reduced rejection-related deaths. Use of these agents, particularly Equine ATG as it seems most favorable overall, should be considered as an alternative to basiliximab.
- Lemtrada (alemtuzumab) / Sanofi
Serum Proteomics Analysis of Lung Transplant Patients Receiving Different Induction Therapies (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1268;
Additionally, the upregulation of immunoglobulins and MCAM in the ATG group suggests a more pro-inflammatory state. The downregulation of fibulin-1 and fetuin-B, elevated in lung diseases, was notable in alemtuzumab over time and in alemtuzumab versus no-induction therapy, suggesting potential benefits for graft survival compared to no-induction therapy, possibly ATG as well.
- | Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. (Pubmed Central) - Jan 17, 2025
Patients initiating heDMAs (natalizumab, alemtuzumab, and ocrelizumab) or meDMAs (interferon beta-1a, interferon beta-1b, fingolimod, teriflunomide, dimethyl fumarate, and glatiramer acetate) were included...In MS, heDMAs were associated with a greater risk of serious infection and UTI compared with meDMAs. These findings suggest the need to carefully monitor and manage the infection risk to optimize the use of heDMAs in MS.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study. (Pubmed Central) - Jan 9, 2025
No significant pharmacodynamic changes or safety concerns were noted in this limited dataset. Alemtuzumab treatment was associated with a low number of new/enlarging T2 lesions in pediatric patients with RRMS and was safe and well tolerated in seven patients during infusion and the initial 4 months.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis. (Pubmed Central) - Dec 28, 2024
ADs developed earlier after ALE infusions, but later after AHSCT except for cytopenias. Neurologists should be attentive to the development of secondary ADs after ALE and AHSCT in MS patients.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal, HEOR: Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study. (Pubmed Central) - Dec 18, 2024
Neurologists should be attentive to the development of secondary ADs after ALE and AHSCT in MS patients. These results indicate early and substantial improvements in patients' perception of their QoL and functioning with alemtuzumab that were sustained over three years.
- | Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Journal: Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? (Pubmed Central) - Dec 10, 2024
However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.
- | Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center. (Pubmed Central) - Dec 3, 2024
ATZ is a high efficacy therapy for active MS, providing long-term remission in a significant proportion of patients. Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells. (Pubmed Central) - Dec 1, 2024
Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs. Ten participants (3 males, 7 females) had blood samples collected at multiple intervals (Day 0, 1, 5, then weekly for 8
- || Lemtrada (alemtuzumab) / Sanofi
P1 data, Journal: SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis. (Pubmed Central) - Nov 15, 2024
P1
The general stabilization of neurological outcomes observed over 60?months underscores the potential long-term benefits of alemtuzumab treatment. Clinicaltrials.gov identifier: NCT02583594.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical and Economic Benefits of Adopting Cladribine Tablets for the Treatment of Relapsing: Remitting Multiple Sclerosis in Public Health Service Institutions in Mexico () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1825;
Cladribine tablets are a safe and effective alternative for RRMS, providing significant savings and improving treatment adherence due to simplified administration. This allows public health institutions to offer effective and economical treatments to patients with RRMS.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
A Network Meta-Analysis of Brazilian Relapsing-Remitting Multiple Sclerosis Drugs in an Early Highly Effective Approach () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_237;
Based on the NMA results, ALE demonstrated superior efficacy in reducing ARR and CDP6. This data can support future assessments of cost-effectiveness and budgetary implications in Brazil, encompassing both the public and private healthcare sectors.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal, Immunomodulating: Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment. (Pubmed Central) - Nov 4, 2024
The study confirms the positive effect of ALEM on clinical and radiological outcomes. We need more data from long-term sequencing studies.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network. (Pubmed Central) - Oct 31, 2024
The relative benefit of selecting higher efficacy treatments may vary depending on patients' baseline brain atrophy risk. Poor outcomes are predicted in individuals with high baseline risk who are treated with low-efficacy DMTs.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis. (Pubmed Central) - Oct 29, 2024
However, despite the difference in the results, Cladribine tablets were cost-effective in all studies compared with injectable drugs. In addition, the present study could be of great importance for policymakers and other beneficiaries regarding the cost-effectiveness of the aforementioned drugs.
- | Mayzent (siponimod) / Novartis, Lemtrada (alemtuzumab) / Sanofi
Journal: Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series. (Pubmed Central) - Sep 12, 2024
In conclusion, the long-term management of patients treated with Alemtuzumab transitioning to secondary progressive MS requires a proactive and multidisciplinary approach. By addressing the challenges associated with treatment limitations and short-term monitoring recommendations while considering alternative therapeutic options like Siponimod, clinicians can optimize outcomes and ensure continuity of care for individuals with MS.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Retrospective data, Review, Journal, Immunomodulating: Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (Pubmed Central) - Sep 10, 2024
Given the relative rarity of PMS, controlled, non-randomised studies on large samples may usefully integrate data from pivotal RCTs. Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Riesgo de c (Pubmed Central) - Sep 3, 2024
Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Risk of skin cancer associated with disease-modifying therapies in multiple sclerosis: a modern comprehensive evidence review. (Pubmed Central) - Sep 3, 2024
Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
- | Lemtrada (alemtuzumab) / Sanofi
Biomarker, Journal: Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. (Pubmed Central) - Sep 3, 2024
During the follow-up period, no changes were identified in the sGFAP values. Alemtuzumab leads to the normalization of sNfL values in MS patients after 2 years of treatment, with no apparent effect on sGFAP values.
- | Ocrevus (ocrelizumab) / Roche, Lemtrada (alemtuzumab) / Sanofi
Observational data, Retrospective data, Journal: Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study. (Pubmed Central) - Aug 31, 2024
Early IgM hypogammaglobulinemia occurred in a high proportion of patients. The evidence of inflammatory activity between ALM courses seemed to increase the risk of MS re-activation on OCR treatment.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021. (Pubmed Central) - Aug 31, 2024
We divided the total number of monthly prescriptions by 12 or 2 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates...In line with global trends, MS prevalence is escalating in Australia, particularly in higher-latitude states. MS prevention is crucial to halt this disturbing trend.
- | Journal: Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. (Pubmed Central) - Aug 31, 2024
There was no evidence for a difference in disability improvement. Cladribine is an effective therapy that can be viewed as a step up in effectiveness from fingolimod, but is less effective than the most potent intravenous MS therapies.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Mistakes in the diagnosis of neuromyelitis optic spectrum diseases lead to wrong therapy and deterioration of patients' condition (Pubmed Central) - Aug 23, 2024
We present a case of late diagnosis of NMOSD that confirms the development of exacerbation in the patient 2 months after the first course of therapy with alemtuzumab prescribed as a highly effective therapy for highly active remitting MS. Timely diagnosis of NMOSD makes it possible to exclude such cases.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal, HEOR, Real-world evidence, Real-world: Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice. (Pubmed Central) - Aug 4, 2024
High-efficacy DMTs have traditionally been reserved for use in people with MS and high disease activity on presentation or breakthrough disease on one or more DMTs, as per the current product labels. The latest evidence from real-world studies suggests that CladT is effective and safe in DMT-na
- | Mavenclad (cladribine) / EMD Serono
Trial primary completion date: DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) - Jul 31, 2024
P4, N=800, Active, not recruiting, Sponsor: The Cleveland Clinic
The latest evidence from real-world studies suggests that CladT is effective and safe in DMT-na Trial primary completion date: Apr 2030 --> Jul 2027
- | Tysabri (natalizumab) / Biogen, Royalty
Journal: Safety and effectiveness of disease-modifying therapies after switching from natalizumab. (Pubmed Central) - Jul 30, 2024
Mean drug survival favored rituximab/ocrelizumab or alemtuzumab over fingolimod (p < 0.001). Our study shows superior effectiveness of rituximab/ocrelizumab and alemtuzumab compared with fingolimod in stable patients switching from NTZ due to JC virus antibody positivity.
- | Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. (Pubmed Central) - Jul 28, 2024
The proportion of pwMS experiencing a moderate/severe relapse and number of relapses declined over pregnancy but increased postpartum. Reinitiation of DMT during the postpartum period was associated with lower risk of relapses, supporting a role for early reinitiation of DMT postpartum.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, Real-world evidence, Real-world: Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions. (Pubmed Central) - Jul 28, 2024
Elevated levels of sNFL must be considered a red-flag suggesting the need of a further clinical monitoring in any circumstance, as it can be indicative of new inflammation, ongoing degeneration or co-morbidities. This study supports the introduction of sNFL quantification in everyday patient management.
- | Lemtrada (alemtuzumab) / Sanofi
Biomarker, Journal, Immune cell: Case report: tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers. (Pubmed Central) - Jul 18, 2024
TDLs can appear 24 months after the second cycle of alemtuzumab treatment in MS. The increase in Th1/Th17 cells could be a candidate biomarker for TDLs in alemtuzumab-treated MS patients.
- Lemtrada (alemtuzumab) / Sanofi
Secondary autoimmunity after Alemtuzumab treatment in MS: Longitudinal immune repertoire study suggests pre-existing predisposition (A2) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1780;
- Lemtrada (alemtuzumab) / Sanofi
Autologous hematopoietic stem cell transplantation vs Alemtuzumab in Multiple Sclerosis: an Italian multicenter study (D1) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1740;
- Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
Disease course in multiple sclerosis (MS) patients switched from natalizumab to alemtuzumab: a multicentre, observational study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1452;
- Lemtrada (alemtuzumab) / Sanofi
Impact of Alemtuzumab on Fatigue, Quality of Life, and Patient/Caregiver Reported Outcomes in Relapsing-Remitting Multiple Sclerosis: Findings from a Real-World Evidence Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1428;
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Cladribine as rescue therapy following multiple sclerosis re-activation after Alemtuzumab (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1305;
- Lemtrada (alemtuzumab) / Sanofi
Investigating effects of monoclonal antibodies therapy: soluble C5b-9 in MS patients treated with Alemtuzumab (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1266;
- Lemtrada (alemtuzumab) / Sanofi
quantification and immunophenotypic characterization of antigen presenting cells in alemtuzumab treated multiple sclerosis patients (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1261;
- Lemtrada (alemtuzumab) / Sanofi
multicenter prospective observational study on real-life experience with alemtuzumab in na (D3) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1222;
- Lemtrada (alemtuzumab) / Sanofi
Effect of Alemtuzumab over sNfL and sGFAP in multiple sclerosis (D3) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_647;